While more research is needed, obesity does play a role in the response to viral infections as well as immunizations, said Kara Dupuy-McCauley, MD, a pulmonologist at the Mayo Clinic in Rochester, Minnesota.
Obesity, which is widespread in the United States, impacts the response to viral infections as well as immune response to vaccines, said Kara Dupuy-McCauley, MD, a pulmonologist at the Mayo Clinic in Rochester, Minnesota, who spoke at CHEST 2022.
Transcript
What is the impact of obesity on viral infections and immunizations?
Well, to summarize the impact of obesity on viral infections and immunizations, I think that we do probably need to do a little bit more work to understand exactly what the impacts are, especially when it comes to obesity and immunizations, because I think that body of literature has a little bit more contradictory information. But I think that it's safe to say that obesity does increase the risk of contracting a viral infection, at least in the specific viral infections where it has been studied. And, it's widely known that obesity also increased the risk of morbidity and mortality as a result of viral infection.
And I think, based on the research that I've done, there probably is a difference in in vaccine response just because of the immunity impairment that comes along with obesity. But I think we do need a little bit more research to understand exactly what the impact is.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
VBID, Heading Into a Third Decade, Looks to Promote Personalization and Access
March 12th 2025Speakers at the 2025 Value-Based Insurance Design summit recapped the accomplishments made over the past 20 years in designing insurance benefits with value in mind and looked ahead to iterations to come.
Read More
Advancing HIV Care With Doravirine and Islatravir: Q&A With Amy Colson, MD, MPH
March 12th 2025New data from the MK-8591A-051 and MK-8591A-052 trials, both investigating the efficacy and safety of 100-mg doravirine and 0.25-mg islatravir as a once-daily 2-drug regimen for virologically suppressed people living with HIV-1, were presented today by Amy Colson, MD, MPH.
Read More